tbuckley/cabot-search huggingface dataset:
Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC).
Authors: Jenny Furlanetto, Christian Thode, Martina Bassy, Carsten Denkert, Claus Hanusch, Jens Bodo Huober, Christian Jackisch, Sherko Kummel, Andreas Schneeweiss, Michael Untch, Peter A. Fasching, Thomas Karn, Frederic Marme, Marion van Mackelenbergh, Volkmar Müller, Christian Schem, Gunter Von Minckwitz, Dominika Strik, Valentina Nekljudova, Sibylle Loibl
Journal: Journal of Clinical Oncology (2017)

10068 Background: Women ≤45 years (yrs) treated with chemotherapy (CT) for EBC have a high risk of developing CIOF. Awareness of CIOF is essential for young women. Methods: 740 patients (pts) aged ≤45yrs treated with anthracycline or taxane-based CT for EBC from 4 German neoadjuvant/adjuvant trials were included. Blood samples were collected at baseline (N=740), end of treatment (EOT n=740), 6 (n=177), 12 (n=113), 18 (n=69), 24 (n=47) months (m) after EOT. Only samples collected in a time sequence were included. Estradiol (E2), Follicle-Stimulating Hormone (FSH) and Anti-Müllerian Hormone (AMH) were centrally assessed. CIOF was defined as FSH &gt;12.4IU/l and E2 &lt;52.2ng/ml and was analysed per timepoint and according to clinical and treatment-related variables. Results: Median age was 40yrs (range 21-45); 57.2% had BMI 18.5-&lt;25, 41.1% ≥25; 32% had luminal, 35.9% HER2+, 32.0% triple-negative BC. Median hormone levels at baseline for pts &lt;30yrs vs 30-40yrs vs ≥40yrs were: FSH 5.2IU/I vs 5.6IU/I vs 6.4IU/I; E2 101ng/l vs 86ng/l vs 88ng/l; AMH 2.14ng/ml vs 1.58ng/ml vs 0.53ng/ml. 85.7% of pts had CIOF at EOT, 62.2% at 6m, 54.0% at 12m, 43.5% at 18m, 38.3% at 24m. Similar results were observed in 47 pts with all timepoint samples available. Older vs younger pts had more frequently CIOF at EOT (≥40yrs 94.6%, 30-40yrs 82.0%, &lt;30yrs 50.0%, p&lt;0.001). CIOF at EOT was not influenced by BMI. CT agents impacted the rate of CIOF (p&lt;0.001; Table 1). Higher rate of CIOF was associated with longer CT duration (12w 58.3%, 16-18w 94.5%, 24w 82.1%; p&lt;0.001) and with dose-dense (ddEC-ddD, weekly PM(Cb), intense-dd (idd) EnPC) vs conventional dosed CT (P/nP-EC q3w, P, Cz) (94.5% vs 78.6%; p&lt;0.001). Conclusions: The majority of young women experienced CIOF after CT for EBC. After 2 yrs 62% of the pts returned to premenopausal hormone levels. Age, CT regimen, duration and density influenced the rate of CIOF and should be taken into account when counseling young women who desire to maintain ovarian function. [Table: see text]
Radiation-associated versus sporadic osteosarcoma: A single-institution experience.
Authors: Brittany Siontis, Emily Roberts, Lili Zhao, Jonathan B. McHugh, Dawn Owen, Laurence H. Baker, J. Sybil Biermann, Scott Schuetze, Rashmi Chugh
Journal: Journal of Clinical Oncology (2017)

11018 Background: Osteosarcoma (osarc) can be a rare complication from radiation (rt) therapy. Radiation-associated osarc (RAO) is reported to have a worse prognosis than non rt-associated osarc with limited objective data comparing the two. We conducted a retrospective study comparing demographics, therapy and outcomes of sporadic osarc (SO) to RAO. This study was confined to adults. Methods: We identified patients (pts) &gt; age 18 years (yr) with osarc treated at our institution between 1990 and 2016 using an institutional database. We categorized tumors as SO or RAO based on history of prior rt within field of osarc. We extracted data on demographics, treatment, and primary malignancy characteristics. Results: We identified 159 pts with osarc, 28 were RAO tumors. Results are in Table 1. Median follow-up was 2.8 yr (0.1-19.6 yr). For RAO, median time from rt to diagnosis was 11.5 yr (1.5-28 yr) with a median cumulative dose of 60 Gy (44-75.8 Gy). Median progression free survival (PFS) and overall survival (OS) were not significantly different in pts presenting with metastatic osarc; PFS 10.3 mo vs 4.8 mo (p=0.45) and OS 15.6 mo vs 6.1 mo (p=0.96) in SO vs RAO pts, respectively. For pts with localized osarc, median relapse-free survival (RFS) and OS were significantly different, not reached vs 12.2 mo (p&lt;0.001) and not reached vs 27.6 mo (p=0.001) in SO vs RAO, respectively. Conclusions: In our series, there was a significant difference in age, size and location of RAO vs non rt-associated osarc. Overall, all osarc pts with metastatic disease at diagnosis fared poorly. Pts presenting with localized RAO had worse outcomes than patients with localized SO. This was not associated with a detectable difference in therapy rendered or treatment effect in resection specimens. [Table: see text]
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS
Authors: Shunsuke Kitajima, Hajime Asahina, Ting Chen, Sujuan Guo, Laura Gutierrez Quiceno, Jillian D. Cavanaugh, Ashley A. Merlino, Shoichiro Tange, Hideki Terai, Jong Wook Kim, Xiaoen Wang, Shan Zhou, Man Xu, Stephen Wang, Zehua Zhu, Tran C. Thai, Chiaki Takahashi, Yujin Wang, Richard Neve, Susanna Stinson, Pablo Tamayo, Hideo Watanabe, Paul T. Kirschmeier, Kwok-Kin Wong, David A. Barbie
Journal: Cancer Cell (2018)
Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC).
Authors: J. Connor Wells, Frede Donskov, Anna Paola Fraccon, Felice Pasini, Georg A. Bjarnason, Jennifer J. Knox, Benoit Beuselinck, Sun Young Rha, Neeraj Agarwal, James Brugarolas, Jae-Lyun Lee, Sumanta K. Pal, Sandy Srinivas, D. Scott Ernst, Ulka N. Vaishampayan, Lori Wood, Robin Simpson, Guillermo de Velasco, Toni K. Choueiri, Daniel Yick Chin Heng
Journal: Journal of Clinical Oncology (2016)

4554 Background: Metastatic papRCC is the second most prevalent type of renal cell carcinoma, next to clear cell RCC (ccRCC). Outcome on therapy in metastatic papRCC remains poorly characterized in the targeted therapy (TT) era. Methods: Data from 5637 patients in the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) were retrospectively analyzed. All patients had metastatic disease and received at least one line of TT. Clinical outcomes were compared between papRCC and ccRCC. Results: 466/5637 (8%) of mRCC patients had papillary histology. Overall survival (OS) in papRCC patients was significantly lower than ccRCC patients, 13.8 months vs 21.9 months (p < 0.0001). Progression free survival (PFS) was also lower in papRCC than ccRCC, 4.7 months vs 7.3 months (p < 0.0001). IMDC prognostic groups were able to stratify patients with metastatic papRCC into favorable, intermediate and poor risk groups (34.1 months, 17.0 months, 6.0 months, respectively (p < 0.0001)). Sunitinib was the most common first line agent (62.9%); no differences in OS were observed between various TTs including mTOR inhibitors. Response rate (RR) to TT was 10.2%, lower than ccRCC (30.5%). 49.5% received second-line therapy. Conclusions: To our knowledge, this is the largest analysis of metastatic papRCC patients. Patients with mRCC with papillary histology have poorer OS, PFS, and RR compared to those with clear cell RCC. PapRCC patients can be stratified using IMDC prognostic factors and this data can be used as benchmarks for planning future clinical trials. Outcome response to TT for ccRCC and papRCC. ccRCC (n = 5016) papRCC (n = 466) Overall Survival (months; 95% CI) 21.85 (20.86-22.93) 13.76 (12.45-16.1) p < 0.0001 PFS (months; 95% CI) 7.33 (6.92-7.72) 4.73 (4.14-5.22) p < 0.0001 IMDC Prognostic Score (months; 95% CI) 41.9 (38.0-44.8) (n = 780) 34.1 (18.6-49.1) (n = 43) p < 0.0001 Favourable 24.0 (22.8-25.1) (n = 2173) 17.0 (13.4-18.7)(n = 200) Intermediate 7.1 (6.5-8.0) (n = 984) 6.0 (4.1-7.9) (n = 116) Poor RR to 1st Line TT n (%) Complete Response 110/4389 (2.5%) 3/391 (0.77%) p < 0.0001 Partial Response 1234/4389 (28%) 37/391 (9.46%) Stable Disease 1950/4389 (44%) 217/391 (55.5%) Progressive Disease 1095/4389 (25%) 134/391 (34.3%)
Outcomes of patients with MYC-expressing aggressive B cell non-Hodgkin lymphomas who fail two or more lines of therapy.
Authors: Daniel Jeffrey Landsburg, Sunita Nasta, Jakub Svoboda, Anthony R. Mato, Stephen J. Schuster, Rachel L Sargent
Journal: Journal of Clinical Oncology (2018)

e19528 Background: Patients (pts) with diffuse large B cell lymphoma (DLBCL) with increased expression of MYC by immunohistochemical staining (IHC) represent > 1/3 of all DLBCL pts with relapsed/refractory (R/R) disease following receipt of curative-intent 2nd line of therapy (2Ltx).1 Here we report analysis of an unselected series of pts with aggressive B cell non-Hodgkin lymphoma (aBNHL) with increased expression of MYC who failed 2Ltx in order to determine outcomes following receipt of subsequent Ltx. Methods: Pts were identified via query of terms “lymphoma” and “MYC” within the University of Pennsylvania Department of Pathology database from 1/1/10-12/31/16. Data were censored at 1/1/18. Pts with DLBCL or BCL unclassifiable/high grade BCL with ≥40% expression of MYC by IHC (MYC+) who received ≥3 Ltx were included. For pts receiving experimental Ltx, outcomes for that Ltx were excluded; however, outcomes following commercially-available (CA) Ltx were included. Results: Thirteen pts were identified with median age at diagnosis 65 years, 35% female, 85% double expressor lymphoma, 31% double hit lymphoma. For 2nd LTx (2Ltx), 91% received platinum-containing tx and 27% subsequent ASCT, with median progression free survival (mPFS) 2.2 months (mo) and duration of response (mDOR) 1.9 mo following 2Ltx. Outcomes following receipt of 3rd through 5th Ltx (3-5Ltx) based upon tx are listed in Table 1 (n = 26 Ltx for the 13 pts). When classified as high risk saaIPI2 prior to the start of 3-5Ltx, overall response rate (ORR) was 0% and mPFS 0.9 mo. Median overall survival (mOS) following 3Ltx was 2.6 mo. Conclusions: Pts w/ MYC+ aBNHL experience poor outcomes following receipt of 3-5Ltx with multiple classes of CA agents, with mOS lower than that of 4.4 mo reported for a historical cohort of DLBCL pts following 3Ltx.1 MYC+ aBNHL pts should be considered as candidates for investigational tx in the multiply-R/R setting. 1Bone Marrow Transplant. 2016 Jan;51(1):51-7. 2 Blood. 2003 Sep 15;102(6):1989-96. Table 1. Tx n High risk saaIPI2 ORR mPFS (mo) mDOR (mo) All 26 73% 19% 1.0 1.2 Cytotoxic 11 63% 27% 1.1 1.0 PD-1 inhibitor 5 80% 20% 0.9 15.1 Ibrutinib 3 67% 0% 0.9 - Lenalidomide 2 50% 50% 3.0 1.2 Venetoclax 2 100% 0% 1.7 - Other 3 100% 0% 0.5 -
Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010.
Authors: Roy S. Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, Jose Luis Perez-Gracia, Ji-Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto Castro, Marcelo Garrido, Misoo C. Ellison, Ayman Samkari, Gregory M. Lubiniecki, Edward B. Garon
Journal: Journal of Clinical Oncology (2017)

9090 Background: We identified factors associated with better OS for previously treated, PD-L1–expressing advanced NSCLC using data from KEYNOTE-010 (NCT01905657; Herbst et al. Lancet. 2016;387:1540-50), in which pembrolizumab had superior OS over docetaxel. Methods: 1033 patients were randomly assigned 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks (Q3W) or docetaxel 75 mg/m 2 Q3W. Response was assessed per RECIST v1.1 by independent central review. Multivariate analyses were performed using a Cox proportional hazards regression model on OS in the pembrolizumab arms. A set of variable selection methods was applied to 19 baseline demographic and disease characteristics, including smoking status, and identified 7 factors that contributed to OS. Data cut was September 30, 2016. Results: Adjusted hazard ratios (HRs) for the factors in the pembrolizumab arm from the model are shown in the Table. Updated OS with an additional 6 months of follow-up from this data lock for KEYNOTE-010 will be presented. Conclusions: While the overall result of KEYNOTE-010 revealed improved OS with pembrolizumab compared with docetaxel in previously treated patients with PD-L1–positive advanced NSCLC, exploratory, post hoc multivariate analyses showed that some laboratory and tumor characteristics such as nonsquamous histology, normal baseline lactate dehydrogenase (LDH), PD-L1 TPS ≥50%, and wild-type EGFR mutation status were associated with better OS among patients treated with pembrolizumab. Clinical trial information: NCT01905657. [Table: see text]
The Mechanical Ventilation–Respiratory Distress Observation Scale as a surrogate of self-reported dyspnoea in intubated patients
Authors: Maxens Decavèle, Frédérick Gay, Romain Persichini, Julien Mayaux, Capucine Morélot-Panzini, Thomas Similowski, Alexandre Demoule
Journal: European Respiratory Journal (2018)

<b>Dyspnoea assessment is challenging in intubated patients. The Mechanical Ventilation–Respiratory Distress Observation Scale could be of major clinical relevance, making breathing comfort evaluation possible in critically ill, noncommunicative patients.</b>http://ow.ly/nhwx30lL13Q
Abstract 19638: Dyssynchrony and Fibrosis Persist After PVC Cessation in a Swine Model of PVC-Induced Cardiomyopathy
Authors: Tomos E Walters, Judit Szilagyi, Christina Alhede, Richard Sievers, Edward Gerstenfeld
Journal: Circulation (2017)

Introduction: Recovery of LV structure and function after eradication of PVCs in PVC-induced cardiomyopathy (PVC-CMPY) is incompletely defined. Hypothesis: That structural and functional changes mi...
Evaluation of adolescents and young adults (AYA) attitudes towards participation in cancer clinical trials.
Authors: Abha A. Gupta, Jennifer A.H Bell, Kate Wang, Victoria Forcina, Seline Tam, Yu-Chung Lin, Nathan Taback, Laura Mitchell, Jeremy Howard Lewin
Journal: Journal of Clinical Oncology (2017)

10047 Background: Participation in clinical trials (CT) for AYA ( &lt; 39 years) remain the lowest of any patient group with cancer. Little is known about the personal barriers to AYA accrual. The aim of this study was to explore AYA attitudes that influence CT participation. Methods: A mixed methods approach included 1) qualitative: interpretive descriptive methodology guided individual semi-structured interviews with 21 AYA for factors influencing CT enrollment and 2) quantitative: AYA and non-AYA (≥40) matched for histology completed Cancer Treatment subscale of Attitudes toward Cancer Trials Scales (ACTS-CT) (Schuber, 2008) and 9 supplementary questions formed from interview analysis. Differences between AYA and non-AYA cohorts were analyzed using the Mann-Whitney U test and ordered logistic regression models were constructed for prediction of the effect of baseline demographics. Results: The major themes influencing CT participation were: (1) family/peer group opinion (2) CT impact on daily/future life (e.g. school; starting a family) and (3) illness severity/psychological readiness for CT information. Surveys were distributed to 61 AYA (median age: 29 years (17-39)); 74 non-AYA (55 (40-88)). Compared with non-AYA, AYA perceived CT to be unsafe/more difficult (Personal Barrier/Safety domain; p = 0.01). AYA were also more concerned with CT interference in their long term goals (p = 0.04). Logistic regression identified participants who had previously been offered a CT (p = 0.01) or who spoke English as their first language (80% of cohort)(p = 0.01) reported less barriers to CT. There were no differences based on age in other domains (Personal Benefits; Personal/Social Value; Trust in CT). In all participants, differences were seen in the Personal Benefits domain if respondents had children (p = 0.05) or were currently working (p = 0.04). Conclusions: Age-related differences in attitudes towards CT suggest that tailored approaches to CT accrual of different patient groups may be warranted. Patient-centered delivery of information regarding CT, particularly for those in whom English is a second language and who are trial-naïve, may improve accrual and warrants further prospective, randomized study.
Relationship between sarcopenia and dose-limiting toxicity (DLT) of sorafenib (SOR) in patients (pts) with advanced radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC) in the phase III DECISION trial.
Authors: Olivier Huillard, Marcia S. Brose, Anne Jouinot, Camille Tlemsani, Jennifer ARRONDEAU, Gerold Meinhardt, Marc Mardoche Fellous, Yoriko De Sanctis, Martin Schlumberger, Francois Goldwasser
Journal: Journal of Clinical Oncology (2017)

e17594 Background: In the phase III DECISION trial comparing SOR with placebo, pts with advanced RAI-R DTC treated with SOR experienced higher rates of adverse events (AEs) than pts with renal cell carcinoma and hepatocellular carcinoma treated with SOR (Brose et al. Lancet 2014). We hypothesized that long-term thyroxine suppressive therapy might result in a high prevalence of sarcopenia, which is known to be associated with increased toxicity of SOR (Antoun et al. Ann Oncol 2010), and we investigated whether sarcopenia at baseline correlated with DLT. Methods: In DECISION, pts with an analyzable baseline lumbar CT scan were eligible. Skeletal muscle cross-sectional area at the third lumbar vertebra was measured, and the median value for each sex defined the cut-off points for sarcopenia. DLT was defined as any AE leading to dose modification; early toxicities occurred ≤30 days after treatment initiation. Results: Of 365 eligible pts, 199 (55%) were sarcopenic (SOR n = 100, placebo n = 99) with large geographic differences: 65/91 Asians (71%), 29/62 North Americans (47%), and 105/212 Europeans (50%). Sarcopenia was 3-fold more frequent than non-sarcopenia in pts ≥75 years of age (19% vs 6%) and was associated with lower body weight (mean [standard deviation]: 71.3 [16.8] vs 80.8 [19.5]; P &lt; 0.0001). Among SOR pts, 76/180 (42%) experienced early DLT of which 44/76 (58%) occurred in sarcopenic pts (P = 0.6497). Among the 90 males, 61 (68%) were sarcopenic and of the 35 males with early DLT, 27 (77%) were sarcopenic. Median time to DLT in sarcopenic vs non-sarcopenic pts who received SOR was 63 vs 95 days, respectively (log-rank P = 0.5328). Conclusions: In this exploratory analysis from DECISION, approximately half of the pts were sarcopenic. In the overall population, no association between sarcopenia and early DLT or DLT were found. Clinical trial information: NCT00984282.
P04.36 Technology for the research of Primary and Partially Passaged Cell Cultures by Human Glioblastoma is necessary for studying the characteristics of a tumor and searching for therapy
Authors: G Pavlova, K Yakovleva, N Pustogarov, E Savchenko, S Goryaynov, A Revishchin, A Kopylov
Journal: Neuro-Oncology (2018)

Glioblastoma is a heterogeneous brain tumor that can be characterized as a socially significant disease with a high mortality threshold. It is believed that the survival prognosis of patients with this diagnosis is extremely unfavorable with an average survival time of only 12–15 months. It should be recognized that the search for new approaches to the study of glioblastoma, which would allow the development of more successful methods of treating this disease, is topical. One of the research areas can be considered the cultivation of cell cultures obtained after surgical removal of the human glioblastoma. It is clear that such cultures are more similar in cellular composition to glioblastoma than cellular immortalized lines. On such cultures, it becomes possible to evaluate both the molecular status of the cell culture and the effectiveness of chemotherapy and radiation. We obtained more than 60 cellular partially transplanted cell cultures with human glioblastomas and evaluated them immunohistochemically, and also studied their molecular profile by RT-PCR using the panel of markers of stem cells, oncomarkers and markers of neural differentiation. One of the most interesting observations within the panel of tumor markers is that simultaneous increased expression of PDGFR and EGFR genes can be a negative prognosis of survival. Additionally, for the PDGFR gene, we showed a positive correlation of marker expression at the level of mRNA and protein. We paid particular attention to the stem cell gene CD133, in view of the positioning of this gene by the world science as a potential marker of stem tumor cells. We have shown that a high level of expression of CD133 can act as a negative prognosis for the survival of patients diagnosed with glioblastoma. Analysis of cell cultures made from human glioblastoma tumor tissue allows studying oncomarkers in dynamics and analyzing the correlation of the effectiveness of therapy with expression of certain markers. The work is supported by RFBR 17-00-00162 (K), 17-00-00157, 18-015-00279
TCT-395 A Propensity-Matched Comparison of Suprasternal and Transfemoral Transcatheter Aortic Valve Replacement: Inominate versus Femoral
Authors: Anna Olds, Kyle Eudailey, Matthew Brinkman, Ming Liao, Sai Pentyala, Catherine Wang, Karina Guaman, Vivian Ng, Poonam Velagapudi, Elliott Elias, Amisha Patel, Torsten Vahl, Omar Khalique, Clifton Lewis, Rebecca Hahn, Vinayak Bapat, Martin Leon, Mustafa Ahmed, Susheel Kodali, Tamim Nazif, Isaac George
Journal: Journal of the American College of Cardiology (2018)
Body mass index, lifestyle factors, and taxane-induced neuropathy in women with breast cancer: The Pathways study.
Authors: Heather Greenlee, Dawn L. Hershman, Zaixing Shi, Marilyn L. Kwan, Isaac J. Ergas, Janise M. Roh, Lawrence H. Kushi
Journal: Journal of Clinical Oncology (2016)

10002 Background: We examined associations of body mass index (BMI) and lifestyle factors with chemotherapy-induced peripheral neuropathy (CIPN) in the Pathways Study, a prospective cohort study of women diagnosed with invasive breast cancer from 2006-2013 in Kaiser Permanente Northern California. Methods: Analyses focused on the 1,608 women who received taxane treatment. Baseline and 6 month interviews assessed BMI (normal: < 25 kg/m2, overweight: 25-30 kg/m2, obese: ≥ 30 kg/m2), fruit/vegetable intake (low: < 35 servings/wk, high: ≥ 35 servings/wk), hours spent on moderate-to-vigorous physical activity (PA) (low: < 2.5 hrs/wk, medium: 2.5-5 hrs/wk, high: > 5 hrs/wk), antioxidant supplement use (non-user, discontinued during chemotherapy, continued user, initiator during chemotherapy), and other characteristics. CIPN was assessed at baseline, 6 and 24 months via 11 neurotoxicity items on the Functional Assessment of Cancer Therapy-Taxane (FACT-NTX). A 10% change in FACT-NTX was considered clinically meaningful. Multivariable logistic regression examined whether BMI, diet, physical activity and antioxidant use were associated with CIPN at 6 and 24 months, adjusted for baseline FACT-NTX score, demographic and clinical covariates. Results: At baseline, 33% of patients were obese, 58% had low fruit/vegetable intake, 31% had low PA, and 10% reported antioxidant supplement use during treatment. In multivariable analyses, worsening of CIPN was less likely to occur in patients with high PA compared to those with low PA at 6 months (OR = 0.6, CI: 0.3-0.9) and 24 months (OR = 0.4, CI: 0.2-0.9), and more likely to occur in obese patients compared to normal weight patients at 24 months (OR = 2.5, CI: 1.2-5.4). Patients who initiated or discontinued antioxidant use during treatment were more likely to have worsening CIPN compared to non-users (initiators: 6 months: OR = 3.9, CI: 1.8-8.3, 24 months: OR = 3.0, CI: 1.0-8.3, P = 0.04; discontinuers: 24 months OR = 2.0, CI: 1.1-3.8). Conclusions: Obesity, low physical activity and change in antioxidant supplement use around the time of chemotherapy initiation were associated with more severe and sustained CIPN for breast cancer patients undergoing taxane treatment.